arcusbio.com - RCUS Income before deduction of interest, taxes and amortization

Graphic logo of Arcus Biosciences Inc (RCUS)

Arcus Biosciences, Inc. (RCUS) maintains a stable moat backed by Gilead, which mitigates financial risks. The GURU.Markets platform displays the EBITDA_Co chart, where 0.00 serves as the current parameter value. Revenue is based on grants and partnership payments for drug development, while production is outsourced to external plants for logistical flexibility, defining the company's current strategic direction.

Profit before payment of interest, taxes and amortization: Arcus Biosciences, Inc. (RCUS) for 11/23/2025 - 11/12/2026

Arcus Biosciences - analytical breakdowns and key metrics (RCUS)

- market value and analyst target forecast:
Market Price Arcus Corp|RCUS - Consensus Target
- issuer market value details:
Market Value Arcus Biosciences|RCUS - Enterprise Value
- book capitalization information:
Net Assets per Share Arcus Biosciences|RCUS - Company Book Value|Market Cap to Net Assets Ratio arcusbio.com|RCUS - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Arcus Biosciences, Inc.|RCUS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Arcus Biosciences Inc|RCUS - Company Debts|Debt to Book Value Ratio Arcus Biosciences|RCUS - Company Long-Term Debt|Short-Term Debt Arcus Biosciences|Critical Liquidity arcusbio.com
- company profitability and valuation multiples indicators:
RCUS - Net Income|Future Net Profit Arcus Biosciences, Inc.|RCUS - P/E Multiple|Future Price to Earnings Multiple arcusbio.com|RCUS - PEG Multiple|Company Value to EBITDA Arcus Biosciences|RCUS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Arcus Biosciences|RCUS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth arcusbio.com|RCUS - Earnings per share growth in current year|Net earnings per share change forecast for next year Arcus Biosciences, Inc.
Analysis of all company metrics:Arcus Corp - RCUS
Mass-produced product of Arcus Biosciences

Developing cancer immunotherapy requires colossal expenditures until patent monopoly is achieved. This metric strips away accounting accruals, capturing the actual cash flow from core operations. It measures the business's factual ability to act as a cash generator, excluding subjective reporting adjustments. It is critical for investors to see the true balance of supply and demand without considering debt obligations. The EBITDA dynamics of Arcus Biosciences, Inc. (RCUS) clearly demonstrate the current operational gap prior to a potential surge in pricing power.

Competitors of Arcus Biosciences, Inc. (RCUS)

NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|ZYME: Operating profit EBITDA|TNGX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Iovance|Operating profit before deduction of amortization Immatics Biotechnologies (IMTX)|Profit before payment of interest, taxes and amortization Xencor, Inc. (XNCR)|Operating profit before deduction of amortization compasstherapeutics.com CMPX|Replimune - Operating profit before deduction of amortization|Operating profit EBITDA Lyell LYEL|IPHA - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology, Inc.) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|Gritstone Bio - Operating profit EBITDA|KA - Operating profit EBITDA|NexImmune (NEXI) - Profit before payment of interest, taxes and amortization|Turnstone Biologics Corp. - Income before deduction of interest, taxes and amortization|VCNX (Vaccinex, Inc) - Operating profit EBITDA|Operating profit before deduction of amortization Harpoon Therapeutics Corp (HARP)